Do analysts recommend APRE or PYRGF?

Aprea Therapeutics currently has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend APRE or ADXS?

Aprea Therapeutics presently has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ABVC or APRE?

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts prefer APRE or ATHE?

Aprea Therapeutics presently has a consensus price target of $4.07, indicating a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Alterity Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, APRE or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aprea Therapeutics $290K 29.29 -$12.60M -$1.54 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Aprea Therapeutics (APRE) Competitors

$0.69 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.70 +0.02 (+2.75%)

As of 06/12/2026 04:14 PM Eastern

Compare

APRE vs. PYRGF, ADXS, GRCE, ABVC, and ATHE

Should you buy Aprea Therapeutics stock or one of its competitors? MarketBeat compares Aprea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aprea Therapeutics include PyroGenesis Canada (PYRGF), Ayala Pharmaceuticals (ADXS), Grace Therapeutics (GRCE), ABVC BioPharma (ABVC), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

How does Aprea Therapeutics compare to PyroGenesis Canada?

Aprea Therapeutics (NASDAQ:APRE) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Aprea Therapeutics and Aprea Therapeutics both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 1.89 beat PyroGenesis Canada's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
PyroGenesis Canada	Neutral

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aprea Therapeutics has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	29.29	-$12.60M	-$1.54	N/A
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A

Aprea Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Aprea Therapeutics currently has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PyroGenesis Canada has a net margin of -115.14% compared to Aprea Therapeutics' net margin of -4,405.59%. PyroGenesis Canada's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

Aprea Therapeutics beats PyroGenesis Canada on 10 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Ayala Pharmaceuticals?

Aprea Therapeutics (NASDAQ:APRE) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Aprea Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	29.29	-$12.60M	-$1.54	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, Aprea Therapeutics had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for Ayala Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Ayala Pharmaceuticals	Neutral

Ayala Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Ayala Pharmaceuticals' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Ayala Pharmaceuticals	N/A	N/A	N/A

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aprea Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Aprea Therapeutics presently has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Aprea Therapeutics beats Ayala Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to Grace Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Aprea Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	29.29	-$12.60M	-$1.54	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

In the previous week, Grace Therapeutics had 4 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Grace Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Grace Therapeutics' score of 0.71 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Grace Therapeutics	Positive

Aprea Therapeutics currently has a consensus target price of $4.07, indicating a potential upside of 492.72%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 172.73%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aprea Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Grace Therapeutics' return on equity of -15.58% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Grace Therapeutics	N/A	-15.58%	-14.51%

Summary

Aprea Therapeutics beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

ABVC BioPharma has higher revenue and earnings than Aprea Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	60.67	-$7.91M	-$0.40	N/A
Aprea Therapeutics	$290K	29.29	-$12.60M	-$1.54	N/A

ABVC BioPharma has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aprea Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 1.89 beat ABVC BioPharma's score of 1.87 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Aprea Therapeutics	Very Positive

ABVC BioPharma has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Summary

Aprea Therapeutics beats ABVC BioPharma on 8 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Alterity Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Aprea Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Alterity Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	29.29	-$12.60M	-$1.54	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Alterity Therapeutics' score of 0.36 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Alterity Therapeutics	Neutral

Alterity Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Alterity Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Alterity Therapeutics	N/A	N/A	N/A

Aprea Therapeutics presently has a consensus price target of $4.07, indicating a potential upside of 492.72%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aprea Therapeutics beats Alterity Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.49M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.45	20.00	24.00	24.42
Price / Sales	29.29	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.45	8.32	10.60	6.82
Net Income	-$12.60M	$23.94M	$3.57B	$337.56M
7 Day Performance	-6.56%	1.84%	0.59%	1.16%
1 Month Performance	-26.23%	-0.04%	1.54%	3.16%
1 Year Performance	-63.70%	44.82%	25.41%	30.60%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	4.3246 of 5 stars	$0.69 flat	$4.07 +492.7%	-63.7%	$8.49M	$290K	N/A	7	Positive News Gap Up High Trading Volume
PYRGF PyroGenesis Canada	N/A	$0.18 -0.1%	N/A	-45.1%	$36.32M	$9.14M	N/A	90	Gap Down
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
GRCE Grace Therapeutics	2.6909 of 5 stars	$2.33 +1.3%	$6.00 +157.5%	-22.5%	$35.59M	N/A	N/A	N/A	Upcoming Earnings Gap Up
ABVC ABVC BioPharma	1.069 of 5 stars	$1.32 -1.5%	N/A	-32.8%	$34.84M	$510K	N/A	30	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. PYRGF, ADXS, GRCE, ABVC, and ATHE

How does Aprea Therapeutics compare to PyroGenesis Canada?

Summary

How does Aprea Therapeutics compare to Ayala Pharmaceuticals?

Summary

How does Aprea Therapeutics compare to Grace Therapeutics?

Summary

How does Aprea Therapeutics compare to ABVC BioPharma?

Summary

How does Aprea Therapeutics compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. PYRGF, ADXS, GRCE, ABVC, and ATHE

How does Aprea Therapeutics compare to PyroGenesis Canada?

Does the media prefer APRE or PYRGF?

Do insiders & institutionals hold more shares of APRE or PYRGF?

Which has higher earnings & valuation, APRE or PYRGF?

Which has more risk and volatility, APRE or PYRGF?

Do analysts recommend APRE or PYRGF?

Is APRE or PYRGF more profitable?

Summary

How does Aprea Therapeutics compare to Ayala Pharmaceuticals?

Which has preferable earnings and valuation, APRE or ADXS?

Does the media refer more to APRE or ADXS?

Is APRE or ADXS more profitable?

Do insiders & institutionals hold more shares of APRE or ADXS?

Which has more volatility & risk, APRE or ADXS?

Do analysts recommend APRE or ADXS?

Summary

How does Aprea Therapeutics compare to Grace Therapeutics?

Which has more risk & volatility, APRE or GRCE?

Do insiders & institutionals believe in APRE or GRCE?

Which has stronger valuation and earnings, APRE or GRCE?

Does the media prefer APRE or GRCE?

Do analysts rate APRE or GRCE?

Is APRE or GRCE more profitable?

Summary

How does Aprea Therapeutics compare to ABVC BioPharma?

Which has preferable valuation & earnings, ABVC or APRE?

Which has more risk & volatility, ABVC or APRE?

Do analysts recommend ABVC or APRE?

Do institutionals & insiders hold more shares of ABVC or APRE?

Does the media favor ABVC or APRE?

Is ABVC or APRE more profitable?

Summary

How does Aprea Therapeutics compare to Alterity Therapeutics?

Which has more volatility & risk, APRE or ATHE?

Which has higher valuation and earnings, APRE or ATHE?

Do insiders & institutionals believe in APRE or ATHE?

Does the media prefer APRE or ATHE?

Is APRE or ATHE more profitable?

Do analysts prefer APRE or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools